Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Materials Select Sector SPDR Fund — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Materials Select Sector SPDR Fund trades at $50.29. Which is the better fit depends on your goals.
| ACAD | XLB | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $53.62 |
52-Week Low | $20.06 | $42.23 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
XLB, the State Street Materials Select Sector SPDR ETF, trades at $51.98, down slightly by 0.06% today. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. The ETF, which provides broad exposure to the U.S. materials sector, lacks disclosed fundamental ratios like P/E and P/S in the provided data. Recent news highlights sector interest, with family offices investing $4.8 billion in materials as of May 23, 2026 (Barron's).
The outlook for XLB is supported by sector rotation into materials amid geopolitical shifts and earnings growth potential, but risks include sensitivity to macroeconomic factors and inflation. Analyst sentiment is mixed, with some viewing valuations as less compelling after recent gains. The ETF's performance will hinge on broader industrial and economic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
